INSUBCONTINENT EXCLUSIVE:
Back in 2018, OurPath emerged as a startup in the U.K
tackling the problem of diabetes
The company helped customers fight the disease, and raised a $3 million round of funding by combining advice from health experts with
tracking technology via a smartphone app to help people build healthy habits and lose weight.Now rebranded as Second Nature, it has raised a
fresh $10 million in Series A funding.New investors include Uniqa Ventures, the venture capital fund of Uniqa, a European insurance group,
and the founders of mySugr, the digital diabetes management platform, which was acquired by health giant Roche .The round also secured the
backing of existing investors including Connect and Speedinvest, two European seed funds, and Bethnal Green Ventures, the early-stage
Impact investor, as well as angels including Taavet Hinrikus, founder of TransferWise.This new injection takes the total investment in the
company to $13 million.Competitors to the company include Weight Watchers and Noom, which provides a similar program and has raised $114.7
million.Second Nature claims to have a different, more intensive and personalized approach to create habit change
The startup claims 10,000 of its participants revealed an average weight loss of 5.9kg at the 12-week mark
Separate peer-reviewed scientific data published by the company showed that much of this weight-loss is sustained at the six-month and
diabetes management.Second Nature was founded in 2015 by Chris Edson and Mike Gibbs, former healthcare strategy consultants, who designed
an activity tracker that links with the app, allowing them to track their weight loss progress and daily step count
They are placed in a peer support group of 15 people starting simultaneously
Each group is coached by a qualified dietitian or nutritionist, who provides participants with daily 1:1 advice, support and motivation via
Throughout the 12-week program, people have access to healthy recipes and daily articles covering topics like meal planning, how to sleep
associated illnesses, which are projected to cost the global economy $1.2 trillion annually by 2025
